Chronic myelogenous leukemia (CML) is a cancer of the blood in which too many granulocytes, a type of white blood cell, build up in the bone marrow.
Normally, bone marrow cells mature into several different types of blood cells. CML affects the young blood cells (called blasts) that develop into a type of white blood cell (called granulocytes). The main function of granulocytes is to destroy bacteria. The blasts, which do not mature and become too numerous, remain in the bone marrow and blood.
Chronic myelogenous leukemia can occur over a period of months or years. A specific chromosome rearrangement is found in the cells of almost all patients with CML. Part of chromosome #9 breaks off and attaches itself to chromosome #22, so that there is an exchange of genetic material between these two chromosomes. This rearrangement changes the position and functions of certain genes, which results in uncontrolled cell growth. Other chromosome abnormalities can also be present.
CML occurs mainly in adults and is rare in children. According to the American Cancer Society, 44,790 leukemia cases are expected in 2009. CML will account for 5,050 of the cases in 2009. How is chronic myelogenous leukemia diagnosed?
In addition to a complete medical history and physical examination, diagnostic procedures for chronic myelogenous leukemia may include:
* blood tests and other evaluation procedures * bone marrow aspiration and/or biopsy - a procedure that involves taking a small amount of bone marrow fluid (aspiration) and/or solid bone marrow tissue (called a core biopsy), usually from the hip bones, to be examined for the number, size, and maturity of blood cells and/or abnormal cells.
Treatment for myelogenous leukemia:
Specific treatment for chronic myelogenous leukemia will be determined by your physician based on:
* your age, overall health, and medical history * extent of the disease * your tolerance for specific medications, procedures, or therapies * expectations for the course of the disease * your opinion or preference
